PeptideStack
5.2kquestions
20kanswers
220users

How many vials from a BCH lot should I send for identity confirmation by mass spectrometry?

Asked 11 Feb 2025Modified 14 months agoViewed 43k times
34

Details up front: BCH · identity confirmation by mass spectrometry.

I have worked this out and I would like someone to find the error, because I suspect there is one.

My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.

How many significant figures are actually justified here?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
mass-spec
mass-spec

Mass spectrometry for identity confirmation: electrospray ionisation, multiple charge states, monoisotopic versus average mass, deconvolution, and…

52 questions
shareeditfollowflag
FB
askedfresh_bac9.7k1611 Feb 2025
8Add the gradient and the column if you have them — half the answer depends on those. – Dr_Priya_Raghunathan 6 months ago
Same question came up on a different supplier and the answer was entirely about the method. – rukhsana_iqbal 8 months ago
add a comment

5 Answers

Accepted answer first, then by votes
56

Accepted answer

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

Worth being precise here: if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

edited 20 May 2025 by b_delacroix — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
BD
answered · acceptedb_delacroix43k3823 Apr 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
61

A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

More usefully, the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
M4
answeredmz_4113101k35831 Mar 2025
40

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Concretely, the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
DB
answeredDr_Fatima_Belkacem18k2611 Apr 2025
26

If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
PH
answeredpetra_hovland35k384 May 2025
3Confirming from the other direction: I ignored the method section once and paid for it. – Dr_Nadia_Farsi 17 days ago
add a comment
19

Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
NT
answeredn_takahashi29k3815 May 2025
2The distinction between purity and content cannot be repeated often enough here. – tadhg_o_riordan 2 months ago
3Adding for future readers: the certificate should carry the lot number, not just a batch code. – Dr_Wren_Halliday 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.